The Week in Review: BeiGene to Raise up to $150 Million This Year

BeiGene, the Beijing area oncology startup, expects to raise between $100 million and $150 million this year from a group of biopharmas and venture capitalists; two China biopharmas, Baotou Dongbao Bio-Tech and Grandhope Biotech, completed IPOs on the ChiNext exchange; ARC Capital Holdings of Hong Kong paid $13 million to acquire a minority interest in Buchang Pharma; MingSight Pharma announced an ophthalmology JV with Shenzhen Relin Medicine; Mindray Medical acquired a controlling stake in a company that makes automated urine sediment analyzers; China may soon institute a policy of mandatory licensing of HIV/AIDS drugs to control costs; the Guangzhou Biotech Island held its opening ceremony and signed MOUs with 30 companies; and Guangzhou Baiyunshan Pharma expanded its antibiotic production facility in Jiexi. More details…. Stock Symbols: (SHE: 300239) (SHE: 300238) (AIM: ARCH) (NYSE: MR) (SHE: 000522)